Truist Raises Encompass Health Price Target to $156 a Share
Truist Securities lifted its price target on Encompass Health shares to $156 a share from $150. Dow Jones Newswires reported the change, citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Truist Securities raised its price target on Encompass Health shares to $156 a share from $150. Dow Jones Newswires reported the change, linking to Benzinga's compilation of ratings actions for the stock.
A single analyst's target change reflects one broker's view and does not by itself signal a shift in the company's financial position. For the broader market the news is usually of minor significance.
why it matters
Price target revisions on individual stocks appear regularly and reflect the view of a specific brokerage. Investors typically weigh them against the company's earnings and the performance of the healthcare sector.
tags
instruments
sources
- Encompass Health Price Target Raised to $156.00/Share From $150.00 by Truist Securities — Dow Jones Newswires, 30 October 2026 at 16:01 UTC
- Kymera Therapeutics Price Target Raised to $150.00/Share From $136.00 by Truist Securities — Dow Jones Newswires, 30 October 2026 at 16:54 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗